Investors are optimistic about HSIC, owing to the strong performance of its Henry Schein One business.
HSIC's Q1 earnings were solid, with full-year EPS guidance of $4.80-$4.94 and analysts expecting $5.27 in 2026. New business units and revamped sales incentives aim to reignite revenue growth after stagnation since 2022; management is optimistic about their impact. Ongoing share buybacks (32% reduction in shares since 2011) continue to support EPS and provide downside support for the stock.
Henry Schein, Inc. (NASDAQ:HSIC ) Q1 2025 Earnings Conference Call May 5, 2025 8:00 AM ET Company Participants Graham Stanley - VP of IR and Strategic Financial Project Officer Stanley Bergman - Chairman and CEO Ron South - SVP and CFO Conference Call Participants Jon Block - Stifel Jason Bednar - Piper Sandler Jeff Johnson - Baird Mike Petusky - Barrington Research Allen Lutz - Bank of America John Stansel - JPMorgan Vik Chopra - Wells Fargo Brandon Vazquez - William Blair Elizabeth Anderson - Evercore ISI Operator Good morning, ladies and gentlemen. Welcome to Henry Schein's First Quarter 2025 Earnings Conference Call.
Although the revenue and EPS for Henry Schein (HSIC) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
HSIC ends the first quarter of 2025 on a mixed note.
Henry Schein (HSIC) came out with quarterly earnings of $1.15 per share, beating the Zacks Consensus Estimate of $1.11 per share. This compares to earnings of $1.10 per share a year ago.
Henry Schein (HSIC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Henry Schein is expected to report impressive Q1 2025 sales in each of its business segment and a positive pace of recovery from the cyber incident.
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock?
HSIC shows bullish price action, momentum, volume, and relative strength, making it an attractive investment with a 2.6 reward-to-risk ratio. The stock is in an uptrend, trading above its 30-week EMA, and has bullish short-term and long-term momentum as indicated by the PPO. Institutional buying supports bullish volume trends, and HSIC has been outperforming the S&P 500 since December 2024.
Henry Schein is the world's largest provider of healthcare products and services for office-based dental and medical practitioners, showing consistent growth through acquisitions. Despite a 3% dip in shares, management's 2025 guidance indicates continued growth, justifying a bullish stance on the stock. The firm reported a 5.8% revenue increase in Q4 2024, driven by organic growth and acquisitions, with significant improvements in net income and operating cash flow.
Henry Schein, Inc. (NASDAQ:HSIC ) Q4 2024 Earnings Conference Call February 25, 2025 8:00 AM ET Company Participants Graham Stanley - Vice President of Investor Relations & Strategic Financial Project Officer Stanley Bergman - Chairman & Chief Executive Officer Ronald South - Senior Vice President & Chief Financial Officer Conference Call Participants Jason Bednar - Piper Sandler Jeffrey Johnson - Baird Allen Lutz - Bank of America John Stansel - JPMorgan Jonathan Block - Stifel Kevin Caliendo - UBS Brandon Vazquez - William Blair Elizabeth Anderson - Evercore ISI Operator Good morning ladies and gentlemen and welcome to Henry Schein's Fourth Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.